Bristol-Myers Squibb Company (BMY)
| Market Cap | 92.86B |
| Revenue (ttm) | 48.03B |
| Net Income (ttm) | 6.04B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.97 |
| PE Ratio | 15.36 |
| Forward PE | 7.20 |
| Dividend | $2.48 (5.44%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 41,934,122 |
| Open | 43.27 |
| Previous Close | 42.60 |
| Day's Range | 43.20 - 45.82 |
| 52-Week Range | 42.52 - 63.33 |
| Beta | 0.34 |
| Analysts | Hold |
| Price Target | 57.54 (+26.13%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.54, which is an increase of 26.13% from the latest price.
News
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript
Bristol-Myers Squibb Company ( BMY) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Chuck Triano Christopher Boerner - CEO & Chairman David Elkins - Executive VP & CFO Cristia...
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Bristol Myers Squibb Co. (NYSE:BMY) reported third-quarter 2025 revenues of $12.22 billion on Thursday, beating the consensus of $11.81 billion, a 3% increase year over year.
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent...
10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)
The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-...
Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.
While total revenue grew in the quarter, competition weighed on the drugmaker's legacy portfolio.
Bristol Myers Squibb Profit Soars, Raises Revenue Guidance
Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.
Bristol Myers beats quarterly revenue estimates on strong Opdivo sales
Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from g...
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025.
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
Bristol-Myers Squibb: Earnings Champion Valued Like A Loser
Bristol-Myers Squibb Company has a strong track record of beating analyst estimates, yet trades at a deeply pessimistic valuation. BMY's Q3 earnings are highly likely to beat consensus, reinforcing co...
Is It Time To Buy BMY Stock?
Bristol-Myers Squibb (NYSE: BMY) stock merits your attention. Why? Because it offers high margins at a discounted price. Here are some details.
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus.
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October ...
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.
Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs
Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including CAG, VZ, MO, BMY, TFC, UDR, KEY, KIM, and RF. Analyst forecasts project top-t...
Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare
Bristol-Myers Squibb is deeply undervalued despite a 23% YTD stock decline, offering compelling value in the healthcare sector. BMY faces significant patent expirations but is proactively mitigating r...
The Play On Bristol-Myers Squibb
Bristol-Myers Squibb has had a recent 30% stock decline amid concerns over patent expirations for key blockbuster drugs through 2028. Despite two FY25 outlook raises and strong cash flow, BMY's revenu...
October's 5 Dividend Growth Stocks With Yields Up To 8.33%
Every month, we screen for high-yield dividend yields, but those that also deliver relatively consistent growth with regular dividend increases. The parameters of the screening also include dividend s...
Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More
The Undercovered Dozen series spotlights 12 lesser-known stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between October 10 and October 16, offering ...
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
REDMOND, Wash. and PRINCETON, N.J.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Final Trade: WMT, AMZN, F, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics
Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA...